AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 659.27B +21.8% |
| Revenue (ttm) | 91.43B +10.4% |
| Net Income | 8.90B +67.7% |
| EPS | 5.03 +68.5% |
| Shares Out | n/a |
| PE Ratio | 74.04 |
| Forward PE | 17.50 |
| Dividend | 1.20 (3.27%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 155 |
| Open | 37.06 |
| Previous Close | 36.95 |
| Day's Range | 36.70 - 37.20 |
| 52-Week Range | 26.89 - 37.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 29, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
AA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% of patient...
AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis
AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have respond...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, o...
AbbVie, Iambic announce multi-year collaboration
AbbVie (ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, announced a multi-year collaboratio...
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in...
AbbVie presents new Vraylar data at Psych Congress 2026
AbbVie (ABBV) presented new Vraylar data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder and bipolar I disor...
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) ...
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in re...
AbbVie’s Allergan Aesthetics presents clinical data on skin quality improvement
AbbVie (ABBV) company Allergan Aesthetics announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatme...
Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie ...
AbbVie Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong growth in immunology, neuroscience, and oncology is driven by a robust pipeline, strategic acquisitions like Apogee, and innovative combination therapies. Market expansion is expected in atopic dermatitis, asthma, Parkinson’s, and multiple myeloma, with significant near-term catalysts and a focus on operational excellence and policy engagement.
Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics. A featured SkinMedica ® R&D panel on exosomes will i...
Ipsen considers building production site in U.S., WSJ says
Ipsen is debating on building a production site in the U.S., with plans the next big plant built will manufacture either its Dysport drug, a rival to AbbVie’s (ABBV) Botox,…
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
AbbVie's migraine treatment meets late-stage study goal
AbbVie said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive treatment of menstrual migraine in adults.
AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine
AbbVie (ABBV) announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide, or CGRP, receptor antagonist, for the preventive treatment o...
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability2,4 Atogepant de...
AbbVie price target raised to $315 from $300 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on AbbVie (ABBV) to $315 from $300 and keeps a Buy rating on the shares. The firm adjusted targets in the…
AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference
Immunology assets SKYRIZI and RINVOQ are driving growth with new indications and strong data, while oncology and neuroscience pipelines advance with innovative therapies and strategic capital allocation. Key milestones include phase III progress in oncology and rapid expansion in immunology.
AbbVie price target raised to $282 from $276 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $282 from $276 and keeps a Buy rating on the shares after updating the firm’s estimates to incorporate zumilokibart following…
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS
AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies, SAT,...
AbbVie's blood cancer drug meets late-stage trial goals
AbbVie said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ra...
AbbVie completes acquisition of Apogee for $135.11 per share in cash
AbbVie (ABBV) announced that it has completed its acquisition of Apogee Therapeutics (APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement,…